Empowered Funds LLC Grows Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Empowered Funds LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 8.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,603 shares of the medical equipment provider’s stock after purchasing an additional 291 shares during the period. Empowered Funds LLC’s holdings in Hologic were worth $294,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cetera Investment Advisers raised its stake in shares of Hologic by 188.9% during the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock worth $1,595,000 after purchasing an additional 13,380 shares during the last quarter. Andra AP fonden raised its position in Hologic by 224.5% during the 2nd quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after buying an additional 66,000 shares during the last quarter. Swedbank AB lifted its stake in shares of Hologic by 5.2% in the 2nd quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock worth $121,060,000 after acquiring an additional 80,575 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after acquiring an additional 582 shares in the last quarter. Finally, Comerica Bank increased its stake in shares of Hologic by 40.9% during the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock worth $8,580,000 after acquiring an additional 31,967 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of analyst reports. Leerink Partners lowered their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Royal Bank of Canada lifted their price target on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Evercore ISI increased their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Tuesday, October 15th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Up 1.0 %

Shares of NASDAQ HOLX opened at $79.73 on Tuesday. The firm’s 50-day moving average is $80.38 and its two-hundred day moving average is $78.38. The company has a market capitalization of $18.52 billion, a PE ratio of 23.94, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. Equities analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.